

# Biostatistics and Clinical Informatics Shared Resource Facility: Biostatistics



"Providing state-of-the-art clinical trial design, statistical analytics, and training "

## BACKGROUND

- The multidisciplinary nature of cancer research studies frequently raises novel design and analytic challenges.
- Biostatisticians play a key role in these studies in a variety of ways:
  - designing studies efficiently to address pertinent hypotheses
  - guiding the creation of appropriate databases
  - ensuring the feasibility of the planned analyses
  - analyzing study data; providing proper interpretation of results
  - developing novel design and analytic methods.

## SERVICES















### Services Supported by NCI-CCSG (Free of Charge)

- Grant development and review
- Interventional - Investigator Initiated Trial (I-IIT) protocol development and review
- Statistical analysis of data directly related to an I-IIT
- Assistance with journal clubs and paper review
- Teaching short courses in design and analysis methodology
- Mentoring for Young Investigator and K awards

### Services Supported by Grants or Contracts

- Statistical analysis of data directly related to grant or a Non-Interventional IIT project
- Assistance with manuscript writing and review
- Assistance with research conferences
- Assistance with identification of research gaps to initiate new research topics

## MEMBERS/EXPERTISE

- |  |   |
|--|---|
| <br><b>Erin Moshier, MS</b><br>Managing Director<br>Group-based trajectory modeling                               | <br><b>Marcio Diniz, PhD</b><br>Co-Director<br>Bayesian clinical trial design                        |
| <br><b>John Mandeli, PhD</b><br>Associate Professor<br>Pilot / Feasibility study design                           | <br><b>Madhu Mazumdar, PhD</b><br>Co-Director<br>Pragmatic clinical trial design                     |
| <br><b>Deukwoo Kwon, PhD</b><br>AD, AMC, Associate Professor<br>Clinical trial design with external control       | <br><b>Himanshu Joshi, PhD</b><br>Assistant Professor<br>Predictive modeling and cancer genomics     |
| <br><b>Seungjun Ahn, PhD</b><br>Assistant Professor<br>Differential network analysis for -Omics data              | <br><b>Xiaoyu Song, PhD</b><br>Associate Professor<br>Integrative data analysis for multi-omics data |
| <br><b>Francesca Petralia, PhD</b><br>Assistant Professor<br>Bayesian algorithm development for -Omics data      | <br><b>Lewis Tomalin, PhD</b><br>Assistant Professor<br>Bioinformatics, Computational Biology       |
| <br><b>Asem Berkalieva, MS</b><br>Senior Biostatistician<br>Group sequential design                             | <br><b>Weijia Fu, MS</b><br>Biostatistician II<br>Multi-omics data analysis                        |
| <br><b>Grace Van Hyfte, MS</b><br>Biostatistician II<br>Longitudinal biomarker and time-to-event joint modeling | <br><b>Mayuri Jain, MS</b><br>Biostatistician I<br>Geographical spatial data analysis              |

## FUNDING MODELS

- Grants:**
- Biostatistician's salary charged at fixed %FTE (negotiated up front during grant development)
  - PhD + MS statisticians recommended for large grants
- Fee for Service Contracts:**
- Charged at a subsidized hourly rate of \$125
  - Requiring a minimum of eight hours of work.

### Long-term Collaboration Contracts:

- Investigator's departmental funds used to support Biostatistician's salary charged at fixed %FTE
- With matching dollars provided by the NCI-CCSG

## SAMPLE PROJECT

### IIT designed with Bayesian Optimal Interval Phase I/II (BOIN12)

#### Goal:


- To assess the safety and efficacy of a combination regimen for patients with Myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) overlap syndrome

#### Why this design is most optimal?

- Maximum tolerated dose (MTD) may not be the optimal dose for treating patients on novel therapies whose efficacy does not increase with dose escalation.
- Identifying the optimal biologic dose (OBD) that optimizes patients' risk-benefit trade-off becomes the target
- BOIN12 design is most optimal for finding OBD as it makes the decision of dose escalation and de-escalation by simultaneously taking account of efficacy and toxicity and adaptively allocating patients to the dose that optimizes the toxicity-efficacy trade-off

#### Why our collaborators are excited about this new design?


- This design is simpler to comprehend and implement because it overcomes the computational and implementation complexity that plagues existing Bayesian phase I/II dose-finding designs



Target Toxicity Rate	0.2	0.25	0.3	0.33	0.35	0.4
Escalation Boundary, $\lambda_u$	0.157	0.197	0.236	0.260	0.276	0.316
De-escalation Boundary, $\lambda_d$	0.238	0.298	0.359	0.395	0.417	0.48

## ACTIVITIES

### Biostatistics Walk-In Clinic

- Aim:** Aid researchers with statistical queries and codes
- Format:** Core members take turns to attend and answer questions
- Meeting Information:** 1-2 pm every 3rd Wednesday of the month on Zoom.
- Co-Organizers:** Seungjun Ahn and Grace Van Hyfte
- Scan this QR code** to register for a particular date and to let us know about your project and questions.
- 


### Biostatics Design and Analysis Workshop

- Aim:** To provide a forum for statistical collaboration on the development, design, and analysis of I-IIT protocols
- Format:** All core members meet to review, critique, and enhance protocol design and analysis plan; trainees and new members attend for learning through discussion
- Meeting Information:** 11-12 pm every Thursday on Teams
- Co-Chair:** Erin Moshier and Marcio Diniz

### Seminar Series (Jointly sponsored with Institute for Health Care Delivery Science)

- Aim:** A live presentation of a set topic where all participants can ask questions and interact to gain a better understanding.
- Format:** All core members join to present or listen to external speakers
- Meeting Information:** 12-1 pm every other Wednesday of the month on Zoom.
- Co-Organizers:** Himanshu Joshi and Deukwoo Kwon

## VISIT OUR WEBSITE



Scan the above QR code to visit our new website and access a PDF of this poster.